Who May Be Candidates and How to Proceed Safely with Your Provider Patients with long-standing remission, no stricture history, normal pancreatitis screening, and strong clinical indication for weight loss may be candidates for GLP-1 trial with heightened monitoring
Chlorine decay in drinking-water transmission and distribution systems: pipe service age effect
Over a million Americans currently source compounded versions via digital clinicsmany operating in gray-market zones
The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported
This tool works as a dose calculator to help you estimate the levels of the drug in your system at any time for varying doses and timing
As oral GLP-1 treatments become more widely available, I think the conversation will now move beyond access, to one of complete treatment